Please ensure Javascript is enabled for purposes of website accessibility

Why Pacific Biosciences of California Stock Is Soaring Today

By Prosper Junior Bakiny - Feb 10, 2021 at 12:26PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Pacific Biosciences is getting an investment from a holding company.

What happened

Shares of gene sequencing specialist Pacific Biosciences of California (PACB 0.18%) are trading higher on Wednesday following the company's announcement that it will receive an investment from Softbank Group (SFTBF 1.99%). As of 12:13 p.m. EST, Pacific Biosciences' stock is up by 18.3% after rising by as much as 31.2% earlier in the day. 

So what

Through one of its subsidiaries, Softbank Group will make a $900 million investment in Pacific Biosciences in the form of senior convertible notes. The notes will have a conversion price of $43.50 per share of the company's common stock, representing a 10% premium over Pacific Biosciences' share price as of the end of yesterday's trading session.

This helps explain, at least in part, why investors are enthusiastic about this deal. The notes will carry an interest rate of 1.5% per year and will mature on Feb. 15, 2028, unless they are converted into shares of common stock on an earlier date.

Man looking at a document with a magnifying glass.

Image source: Getty Images.

The investment suggests that Softbank Group has high hopes for Pacific Biosciences' future. "We believe that [Pacific Biosciences'] HiFi sequencing will be the de facto standard tool for population genomics fundamentally altering the practice of healthcare," said Akshay Naheta, CEO of Softbank Management.

Now what 

Should investors be equally bullish on Pacific Biosciences? It is worth noting that the healthcare company has had a noisy past year. First, a merger attempt between Pacific Biosciences and Illumina (ILMN 1.14%) fell through in early 2020. Second, the pandemic disrupted Pacific Biosciences' business and hurt its financial results.

Third, the company made some notable changes to its leadership team last year. Looking forward, Pacific Biosciences is counting on several of its products to help it deliver excellent performances, including the Sequel IIe gene-sequencing system it launched last year.

This system is cheaper and more accurate than its predecessors. With that as an overview, while Pacific Biosciences is worth considering, I'd wait until after the pandemic subsides to initiate a position. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pacific Biosciences of California, Inc. Stock Quote
Pacific Biosciences of California, Inc.
PACB
$5.61 (0.18%) $0.01
Illumina, Inc. Stock Quote
Illumina, Inc.
ILMN
$243.49 (1.14%) $2.74
SoftBank Group Corp. Stock Quote
SoftBank Group Corp.
SFTBF
$40.00 (1.99%) $0.78

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/23/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.